Kiersten Stead

Grove Biopharma Inc. is a private biotechnology company based in Chicago, Illinois. It is pioneering its Bionic Biologics™ platform to develop therapies that target previously intractable intracellular disease targets.

NILO Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.

Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments and has entered into a strategic agreement with Eli Lilly. Radionetics is advancing a pipeline of first-in-class small molecule radioligands targeting G protein coupled receptors for the treatment of a broad range of cancers, including breast cancer, lung cancer, and other indications of high unmet need.

Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.

At Latus Bio, we are developing novel therapeutics for CNS disorders with our revolutionary AAV capsids. We have developed capsid variants with unprecedented potency, specificity, and trophism. All of our capsids were designed with a particular disease in mind, in order to find the right capsid and the right route of administration to target the most relevant brain regions and cell types for each specific indication. Founded on the groundbreaking work of Professor Beverly Davidson from the Childrens Hospital of Philadelphia, Latus Bio is committed to transforming patient care through targeted, potent, and safe gene therapies. We are focused on CNS diseases such as CLN2 (Batten Disease) and Huntington’s Disease, aiming to fundamentally alter the course of these challenging conditions by always putting the patients first. We are not just developing therapies; we are revolutionizing the future of healthcare with innovations that reduce therapeutic load, enhance safety, facilitate manufacturing, and expand access. Latus Bio is powered by a diverse team of visionary scientists, clinicians, and industry leaders dedicated to tackling some of the most complex neurological disorders. With a robust pipeline and a strategy to enter clinical trials by late 2025, we are poised to make significant strides quickly. Be part of this transformative movement at Latus Bio. Lets unlock the potential of gene therapy to bring hope and healing to millions around the globe. Learn more about our mission, our people, and our promise at www.latusbio.com and connect with us on LinkedIn to follow our progress.

Elo Life Systems is reimagining the future of food – focusing on ingredients that empower consumers to feel good about the food they eat every day. From unique plant-based sweeteners to saving crops like the banana from extinction, Elo harnesses the untapped potential of nature to make food tastier, healthier and resilient while requiring less from the planet.

At Stemson Therapeutics, we envision a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair.

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).

Verdant Robotics’ Sharpshooter smart sprayer assists growers in significantly reducing labor costs by 50% or more, all while utilizing 96% fewer inputs. Whether weeding, thinning, pollinizing, or fertilizing, Verdant’s AI-driven Bullseye Technology determines real-time application decisions and precisely delivers atoms on target with millimeter precision. Growers gain access to new value, cover more ground, increase yields, and cultivate higher-value produce through Verdant’s simultaneous multi-chemical application and agronomic insights. Verdant’s Sharpshooter is available today for use in any crop—specialty, fixed infrastructure, conventional, or organic—around the clock. Verdant Robotics: where innovation drives efficiency. Learn more at www.verdantrobotics.com

We’re on a journey to Grow the Future of Materials. How? By unlocking the unique properties of mycelium, the root structure of mushrooms. Our patented technology, Fine Mycelium™, unleashes a new class of materials crafted from nature, engineered for performance, and built for a resilient future. Our impact on future generations steers our innovations today. From our expertise in mycology and materials science to our manufacturing innovations, we’re creating new possibilities for industry. We’re an outstanding team of scientists, engineers, product experts, artists, leaders—and you.

GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Plexium is the premier, next-generation targeted protein degradation company, seeking to discover a wide range of monovalent target protein degraders that address the limitations of PROTACs and cereblon. The company’s platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases.

We are insanely devoted to building never-before-attempted, head-turning agriculture solutions to make the next generation farmer.

Grove Biopharma Inc. is a private biotechnology company based in Chicago, Illinois. It is pioneering its Bionic Biologics™ platform to develop therapies that target previously intractable intracellular disease targets.

NILO Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.

Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments and has entered into a strategic agreement with Eli Lilly. Radionetics is advancing a pipeline of first-in-class small molecule radioligands targeting G protein coupled receptors for the treatment of a broad range of cancers, including breast cancer, lung cancer, and other indications of high unmet need.

Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.

At Latus Bio, we are developing novel therapeutics for CNS disorders with our revolutionary AAV capsids. We have developed capsid variants with unprecedented potency, specificity, and trophism. All of our capsids were designed with a particular disease in mind, in order to find the right capsid and the right route of administration to target the most relevant brain regions and cell types for each specific indication. Founded on the groundbreaking work of Professor Beverly Davidson from the Childrens Hospital of Philadelphia, Latus Bio is committed to transforming patient care through targeted, potent, and safe gene therapies. We are focused on CNS diseases such as CLN2 (Batten Disease) and Huntington’s Disease, aiming to fundamentally alter the course of these challenging conditions by always putting the patients first. We are not just developing therapies; we are revolutionizing the future of healthcare with innovations that reduce therapeutic load, enhance safety, facilitate manufacturing, and expand access. Latus Bio is powered by a diverse team of visionary scientists, clinicians, and industry leaders dedicated to tackling some of the most complex neurological disorders. With a robust pipeline and a strategy to enter clinical trials by late 2025, we are poised to make significant strides quickly. Be part of this transformative movement at Latus Bio. Lets unlock the potential of gene therapy to bring hope and healing to millions around the globe. Learn more about our mission, our people, and our promise at www.latusbio.com and connect with us on LinkedIn to follow our progress.